Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.

Name: Αlpha¹ Rigor Record — Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.
Item: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.
Rating: 96
Author: Αlpha¹

Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, Hsieh YT, Sun YS, Vroom MM, Farris CM, Ma Y, de Kam ML, Radanovic I, Vissers MFJM, Mirski D, Shareghi G, Shahnawaz M, Singer W, Kremer P, Groeneveld GJ, Yu HJ, Dodart JC

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.25★ (Critical), 0 critical, 3 high issues for “Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.25 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions4

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1 randomized controlled trial of an active immunotherapeutic for Parkinson's disease. The main strengths are rigorous randomization/blinding, detailed reporting of demographics and ethics, and appropriate statistical methods. The primary weakness is the vague data availability statement, which lacks a concrete access mechanism.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The study type is interventional (phase 1 RCT). Non-applicable sub-criteria (e.g., cell line authentication, housing conditions, IACUC) were excluded. The statistics verification covered only 5 tests; the rest were not machine-verified.

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction extensively cites prior research on α-synuclein's role in PD, previous immunotherapy trials (including failed phase 2 trials), and the lack of target-engagement biomarkers. It acknowledges limitations of prior work (e.g., failed trials, need for better biomarkers) and explains how the study addresses them (using αSyn-SAA as an exploratory biomarker). The rationale for testing UB-312 is logically derived from preclinical and Part A data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on α-synuclein pathology, immunotherapies, and the need for biomarkers, and clearly links this to the study objectives.

Evidence

direct quote[Introduction, paragraph 2]

“Two phase 2 clinical trials recently failed to demonstrate efficacy of monoclonal antibodies against αSyn”